A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

To be considered for this study, you would generally need to be an adult, aged 18 or older. A key requirement is that your advanced solid cancer must be missing a specific gene called MTAP. Your doctor will be able to test your tumor for this. You'll also need to have cancer that can't be cured by standard surgery or radiation alone, and your doctors must be able to measure your cancer to see if the treatment is working.

Beyond your cancer diagnosis, the medical team will check your general health to make sure you're well enough to take part. This includes checking how your heart, lungs, kidneys, and liver are working. You'll also need to be able to swallow pills, as the study drug is taken by mouth, and be willing to keep a record of when you take it.

In some specific parts of the study, you might need to provide a recent tumor sample (either existing tissue or sometimes a new biopsy) for testing. This helps researchers understand more about your cancer and how the treatment might affect it.

If you decide to join this study, you'll first have a number of health checks and tests to make sure it's suitable for you. Once enrolled, you'll take the study medication, Anvumetostat, likely as tablets you swallow. In some cases, you might also receive the cancer drug Docetaxel, which is given through a drip.

You will have regular hospital visits for check-ups, blood tests, scans, and to discuss any side effects you might be experiencing. These visits help the study team monitor your health and how the treatment is working. The exact number and frequency of visits will depend on which part of the study you are in, but they will be clearly explained to you before you start. You'll also be asked to keep track of when you take your medicine at home. The study will involve ongoing treatment and follow-up for a period that your doctor can explain, continuing as long as the treatment is helping and side effects are manageable.